Cargando…
Effectiveness and Safety of Dabrafenib in the Treatment of 20 Chinese Children with BRAF(V600E)-Mutated Langerhans Cell Histiocytosis
PURPOSE: We sought to investigate the effectiveness and safety of dabrafenib in children with BRAF(V600E)-mutated Langerhans cell histiocytosis (LCH). MATERIALS AND METHODS: A retrospective analysis was performed on 20 children with BRAF(V600E)-mutated LCH who were treated with dabrafenib. RESULTS:...
Autores principales: | Yang, Ying, Wang, Dong, Cui, Lei, Ma, Hong-Hao, Zhang, Li, Lian, Hong-Yun, Zhang, Qing, Zhao, Xiao-Xi, Zhang, Li-Ping, Zhao, Yun-Ze, Li, Na, Wang, Tian-You, Li, Zhi-Gang, Zhang, Rui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Cancer Association
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812025/ https://www.ncbi.nlm.nih.gov/pubmed/32972045 http://dx.doi.org/10.4143/crt.2020.769 |
Ejemplares similares
-
Circulating cell-free BRAF V600E during chemotherapy is associated with prognosis of children with Langerhans cell histiocytosis
por: Cui, Lei, et al.
Publicado: (2020) -
Dabrafenib, alone or in combination with trametinib, in BRAF V600–mutated pediatric Langerhans cell histiocytosis
por: Whitlock, James A., et al.
Publicado: (2023) -
Clinical Research of Pulmonary Langerhans Cell Histiocytosis in Children
por: Wang, Dong, et al.
Publicado: (2018) -
BRAF V600E-Positive Congenital Multisite Langerhans Cell Histiocytosis
por: Prada Avella, Maria Camila, et al.
Publicado: (2020) -
Cutaneous Langerhans cell histiocytosis with gastrointestinal involvement treated with dabrafenib
por: Stewart, Jacob R., et al.
Publicado: (2017)